The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5-10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University and University Hospital 779 00 Olomouc Czech Republic

Department of Urology University Hospital 779 00 Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

See more in PubMed

Pereira-Azevedo N., Verbeek J.F.M., Nieboer D., Bangma C.H., Roobol M.J. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. Transl. Androl. Urol. 2018;7:18–26. doi: 10.21037/tau.2017.12.21. PubMed DOI PMC

Raja N., Russell C.M., George A.K. Urinary markers aiding in the detection and risk stratification of prostate cancer. Transl. Androl. Urol. 2018;7:436–442. doi: 10.21037/tau.2018.07.01. PubMed DOI PMC

Cucchiara V., Cooperberg M.R., Dall’Era M., Lin D.W., Montorsi F., Schalken J.A., Evans C.P. Genomic Markers in Prostate Cancer Decision Making. Eur. Urol. 2018;73:572–582. doi: 10.1016/j.eururo.2017.10.036. PubMed DOI

Kearns J.T., Lin D.W. Improving the Specificity of PSA Screening with Serum and Urine Markers. Curr. Urol. Rep. 2018;19:80. doi: 10.1007/s11934-018-0828-6. PubMed DOI

Stephan C., Ralla B., Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim. Biophys. Acta Rev. Cancer. 2014;1846:99–112. doi: 10.1016/j.bbcan.2014.04.001. PubMed DOI

Nicholson A., Mahon J., Boland A., Beale S., Dwan K., Fleeman N., Hockenhull J., Dundar Y. The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: A systematic review and economic evaluation. Health Technol. Assess. 2015;19:1–192. doi: 10.3310/hta19870. PubMed DOI PMC

Parekh D.J., Punnen S., Sjoberg D.D., Asroff S.W., Bailen J.L., Cochran J.S., Concepcion R., David R.D., Deck K.B., Dumbadze I., et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur. Urol. 2015;68:464–470. doi: 10.1016/j.eururo.2014.10.021. PubMed DOI

Vickers A.J., Eastham J.A., Scardino P.T., Lilja H. The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology. 2016;91:12–18. doi: 10.1016/j.urology.2015.12.054. PubMed DOI PMC

Ahmed H.U., El-Shater Bosaily A., Brown L.C., Gabe R., Kaplan R., Parmar M.K., Collaco-Moraes Y., Ward K., Hindley R.G., Freeman A., et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. Lancet. 2017;389:815–822. doi: 10.1016/S0140-6736(16)32401-1. PubMed DOI

Perlis N., Al-Kasab T., Ahmad A., Goldberg E., Fadak K., Sayyid R., Finelli A., Kulkarni G., Hamilton R., Zlotta A., et al. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. J. Urol. 2018;199:1182–1187. doi: 10.1016/j.juro.2017.11.074. PubMed DOI

Smith B., Agarwal P., Bhowmick N.A. MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr. Relat. Cancer. 2017;24:R157–R172. doi: 10.1530/ERC-16-0525. PubMed DOI PMC

Helsmoortel H., Everaert C., Lumen N., Ost P., Vandesompele J. Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope? Non-Coding RNA Res. 2018;3:64–74. doi: 10.1016/j.ncrna.2018.05.001. PubMed DOI PMC

Larsen L.K., Jakobsen J.S., Abdul-Al A., Guldberg P. Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration. J. Urol. 2018;200:749–757. doi: 10.1016/j.juro.2018.04.067. PubMed DOI

Kral M., Grepl M., Hruska F., Hradil D., Rajmon P., Student V., Knillova J., Bouchal J. Effect of prostatic tissue inflammation on prostate cancer markers in urine. Eur. Urol. Suppl. 2015;14:e1285. doi: 10.1016/S1569-9056(15)30322-5. DOI

De Luca S., Passera R., Fiori C., Bollito E., Cappia S., Mario Scarpa R., Sottile A., Rondone D.F., Porpiglia F. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. Urol. Oncol. 2015;33:424.e17–424.e23. doi: 10.1016/j.urolonc.2015.05.032. PubMed DOI

Smelov V., Novikov A., Brown L.J., Eklund C., Strokova L., Ouburg S., Morre S.A., Dillner J. False-positive prostate cancer markers in a man with symptomatic urethral Chlamydia trachomatis infection. Int. J. STD AIDS. 2013;24:501–502. doi: 10.1177/0956462412472805. PubMed DOI

Sequeiros T., Bastaros J.M., Sanchez M., Rigau M., Montes M., Placer J., Planas J., de Torres I., Pegtel D.M., Doll A., et al. Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Prostate. 2015;75:1102–1113. doi: 10.1002/pros.22995. PubMed DOI

Jamaspishvili T., Kral M., Khomeriki I., Vyhnankova V., Mgebrishvili G., Student V., Kolar Z., Bouchal J. Quadriplex model enhances urine-based detection of prostate cancer. Prostate Cancer Prostatic Dis. 2011;14:354–360. doi: 10.1038/pcan.2011.32. PubMed DOI

Fujita K., Pavlovich C.P., Netto G.J., Konishi Y., Isaacs W.B., Ali S., De Marzo A., Meeker A.K. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Hum. Pathol. 2009;40:924–933. doi: 10.1016/j.humpath.2009.01.004. PubMed DOI PMC

Joosse S.A., Gorges T.M., Pantel K. Biology, detection and clinical implications of circulating tumor cells. EMBO Mol. Med. 2015;7:1–11. doi: 10.15252/emmm.201303698. PubMed DOI PMC

Cao C., Wang Q., Li Q., Zhao Q., Wang J.Q., Liu Y. Development and Preliminary Clinical Application of Circulating Tumor Cell Detection System for Prostate Cancer. J. Biomed. Nanotechnol. 2019;15:612–620. doi: 10.1166/jbn.2019.2706. PubMed DOI

Zhang Y., Linn D., Liu Z., Melamed J., Tavora F., Young C.Y. EBP1, an Erb3—Binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol. Cancer Ther. 2008;7:3176–3186. doi: 10.1158/1535-7163.MCT-08-0526. PubMed DOI PMC

Hessels D., Klein Gunnewiek J.M.T., van Oort I., Karthaus H.F.M., van Leenders G.J.L., van Balken B., Kiemeney L.A., Witjes J.A., Schalken J.A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003;44:8–16. doi: 10.1016/S0302-2838(03)00201-X. PubMed DOI

Kucerova R., Bienova M., Kral M., Bouchal J., Trtkova K.S., Burdova A., Student V., Kolar Z. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer. J. Eur. Acad. Dermatol. Venereol. 2015;29:91–96. doi: 10.1111/jdv.12468. PubMed DOI

Wilson M.L., Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin. Infect. Dis. 2004;38:1150–1158. doi: 10.1086/383029. PubMed DOI

Dos Santos J.C., Weber L.P., Perez L.R.R. Evaluation of urinalysis parameters to predict urinary-tract infection. Braz. J. Infect. Dis. 2007;11:479–481. doi: 10.1590/S1413-86702007000500008. PubMed DOI

Musher D.M., Thorsteinsson S.B., Airola V.M., II. Quantitative urinalysis. Diagnosing urinary tract infection in men. JAMA. 1976;236:2069–2072. doi: 10.1001/jama.1976.03270190025022. PubMed DOI

Ploussard G., Haese A., van Poppel H., Marberger M., Stenzl A., Mulders P.F.A., Huland H., Bastien L., Abbou C.-C., Remzi M., et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: Does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int. 2010;106:1143–1147. doi: 10.1111/j.1464-410X.2010.09286.x. PubMed DOI

Auprich M., Augustin H., Budäus L., Kluth L., Mannweiler S., Shariat S.F., Fisch M., Graefen M., Pummer K., Chun F.K.-H. A comparative performance analysis of total prostate-specifi c antigen, percentage free prostate-specific antigen, prostate-specifi c antigen velocity and urinary prostate cancer gene 3 in the fi rst, second and third repeat prostate biopsy. BJU Int. 2012;109:1627–1635. doi: 10.1111/j.1464-410X.2011.10584.x. PubMed DOI

Leyten G.H.J.M., Hessels D., Jannink S.A., Smit F.P., de Jong H., Cornel E.B., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C., et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 2014;65:534–542. doi: 10.1016/j.eururo.2012.11.014. PubMed DOI

Van Neste L., Hendriks R.J., Dijkstra S., Trooskens G., Cornel E.B., Jannink S.A., de Jong H., Hessels D., Smit F.P., Melchers W.J.G., et al. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur. Urol. 2016;70:740–748. doi: 10.1016/j.eururo.2016.04.012. PubMed DOI

Hendriks R.J., van der Leest M.M.G., Dijkstra S., Barentsz J.O., Van Criekinge W., Hulsbergen-van de Kaa C.A., Schalken J.K., Mulders P.F.A., van Oort I.M. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate. 2017;77:1401–1407. doi: 10.1002/pros.23401. PubMed DOI

McKiernan J., Donovan M.J., Margolis E., Partin A., Carter B., Brown G., Torkler P., Noerholm M., Skog J., Shore N., et al. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur. Urol. 2018;74:731–738. doi: 10.1016/j.eururo.2018.08.019. PubMed DOI

Tomlins S.A., Day J.R., Lonigro R.J., Hovelson D.H., Siddiqui J., Kunju L.P., Dunn R.L., Meyer S., Hodge P., Groskopf J., et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur. Urol. 2016;70:45–53. doi: 10.1016/j.eururo.2015.04.039. PubMed DOI PMC

Sanda M.G., Feng Z., Howard D.H., Tomlins S.A., Sokoll L.J., Chan D.W., Regan M.M., Groskopf J., Chipman J., Patil D.H., et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017;3:1085–1093. doi: 10.1001/jamaoncol.2017.0177. PubMed DOI PMC

Zhou Y., Li Y., Li X., Jiang M. Urinary Biomarker Panel to Improvement in Predicting Prostate Biopsy Result in Chinese Men with PSA 4-10 nj/mL. Biomed. Res. Int. 2017;2017:1–9. PubMed PMC

Deras I.L., Aubin S.M.J., Blase A., Day J.R., Koo S., Partin A.W., Ellis W.J., Marks L.S., Fradet Y., Rittenhouse H., et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008;179:1587–1592. doi: 10.1016/j.juro.2007.11.038. PubMed DOI

De Luca S., Passera R., Milillo A., Coda R., Randone D.F. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score. BJU Int. 2012;110:778–782. doi: 10.1111/j.1464-410X.2012.11645.x. PubMed DOI

Vlaeminck-Guillem V., Bandel M., Cottancin M., Rodriguez-Lafrasse C., Bohbot J.-M., Sednaoui P. Chronic prostatitis does not influence urinary PCA3 score. Prostate. 2012;72:549–554. doi: 10.1002/pros.21457. PubMed DOI

Schaeffer E.M. Re: Chronic prostatitis does not influence urinary PCA3 score. J. Urol. 2012;188:2242. doi: 10.1016/j.juro.2012.08.077. PubMed DOI

New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management